A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
Clinical trial NCT05291689 · COMPLETED
Trial details
- NCT number
- NCT05291689
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-13
- Primary completion
- 2023-10-18
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.